Global Lazy Eye Market Size, Share, Forecast Report, 2020-2027

The lazy eye disease or amblyopia is a childhood condition affecting the development of vision. In this disease, it the brain does not acknowledge the images seen by the eye. The condition affects only one of the eye but can further result in the impairment of vision in the other eye. Increasing prevalence of the lazy eye diseases and growing child population are the major drivers for the market growth during the forecast period. According to the National Health Service, U.K, 1 in every 50 children is predicted to develop a lazy eye. Moreover, in 2016, it was reported that there were approximately 4014.3 million children within the U.K. Additionally, rising healthcare expenditures and increasing R&D by the major market players fuel the market growth. However, lack of awareness and unavailability of the effective treatment procedures may restrain the market growth during the forecast period.

The lazy eye market is expected to grow at an approximate CAGR of 7.8% during the forecast period.
Segmentation

The global lazy eye market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of the type, the market is segmented into strabismic amblyopia, refractive amblyopia, deprivation amblyopia, and others. On the basis of the diagnosis, the market is segmented into general eye test, squint test, and others. On the basis of the treatment, the market is segmented into corrective eyewear, eye patches, surgery, atropine eye drops, and others. The corrective eyewear segment is sub-segmented into glasses, contact lenses, and others. On the basis of the end-users, the market is segmented into eye care clinics, hospitals, retail pharmacies, and others.
Key players in global lazy eye market

The key players in the global lazy eye market are inclusive of Pfizer Inc. (U.S.), TCI Chemicals (India) Pvt. Ltd. (India), Adwia Pharmaceuticals Co. (Egypt), 3M (U.S.), Bausch & Lomb Incorporated. (U.S.), Rebion (U.S.), Vivid Vision, Inc. (U.S.), Johnson and Johnson Services, Inc. (U.S.), and others.